All the Drug Class Drugs
Anti HIV, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Emtricitabine 200 mg, Tenofovir Alafenamide 10 mg, 25 mg. F.C. TABS.:30. Dosage must be ajust. individ.
Indicated in comb. with other antiretrovir. agents for the tmt. of adult. and adolesc. (aged 12 yrs. and older with bdy. wt. at least 35 kg) infect. with human immunodeficiency virus type 1 (HIV-1).
Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Emtricitavine 200 mg, Rilpivirine (as HCl) 25 mg, Tenofovir Disoproxil (as Fumarate) 245 mg. F.C. TABS: 30. Adults: 1 tab dly with
meal. Under 18 yrs: Not recommend.
Over 65 yrs: use with caution. Not
recommend. in pts. with CLcr < 50 ml/
min. See lit.
Comb. of emtricitabine, tenofovir
disoproxil fumarate and rilpivirine for use
as a complete regimen for the tmt of HIV-1
infect. in adult pts with no antiretrov. tmt
hist. and with HIV-1 RNA less than or equal
to 100,000 copies/mL at the start of ther.,
and in certain virologic. suppress. (HIV-1
RNA <50 copies/mL) adult pts on a stable
antiretrov. regimen at start of ther. in order
to replace their curr. antiretrov. tmt
C/I: Hypersens. to act. subst. or to any
excip., co-admin. with CYP3A induc. and
gastric pH incr.: anticonvuls. –
antimycobacter. – rifampin, rifapentine;
PPI – dexlansoprazole, esomeprazole,
lansoprazole, omeprazole, antoprazole,
rabeprazole; glucocorticoid systemic
dexamethasone (more than a single
dose); St. John’s wort (Hypericum
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Abacavir 600 mg, Lamivudine 300 mg. The recommend. dose for Adult. and child. >12 weigh. at least 40 kg, is1 tab×1/d. See lit. Tmt. of HIV infec. in adult. and in child. over the age of 12 yrs.
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Lamivudine 100 mg. TAB: 100 mg: x 30 tablets.
Adults 100 mg x 1 dly. Safety and
effectiveness of beyond 1 yr have not
been established and the optimum
duration of treatment is not known.
Pediatric Patients (2 to 17 years of age)
3 mg/kg once daily up to a maximum
daily dose of 100 mg. Safety and
effectiveness of treatment beyond 1 year
have not been established and the
optimum duration of treatment is not
Dose Adjustment: It is recommended
that the doses be adjusted in
accordance with renal function.
Treatment of chronic hepatitis B
associated with the evidence of hepatitis B
viral (HBV) replication and active liver
inflammation in adults and also in
children and adolescents aged 2 to 17
C/I: Known hypersens. to lamivudine or
to any other ingredient of the product.
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Lamivudine 150 mg, Zidovudine 300 mg. TABS.: 60. Adult. /adolesc. ≥30 kg: 1 tab.
Child. 21 kg - 30 kg: 1/2 tab. taken in
the morn. and 1 whole tab. taken in the
Child. 14 kg- 21 kg: 1/2 tab.×2/d.
Elderl.: decreas. in renal func. and
alterat. of haemat. param. must be
taken in consider.
Renal impair.: Dosage adjust. is require.
in pts. with a CrCl < 50 ml/min. Its
recommend. separate preparat. of
lamivudine, zidovudine should be
admin. to these pts.
Hep. impair.: Dosage adjust. may be
necess. in pts.
Its recommend.that separate preparat.
of lamivudine, zidovudine should be
admin. to these pts.
Dosage adjust. in pts. with hemat.
adverse react.: Dosage adjust. may be
neces. if the Hb level falls below 9 g/dl
or 5.59 mmol/l or the neutrophil count
falls below 1.0 x 109/l. Separate prepar.
of zidovudine, lamivudine should be used. May be admin. with or without
food. See lit.
Antiretroviral comb. ther. for the tmt. of
HIV infec. adults&adolesc. over the age of
C/I: Pts. with known hypersens. to
lamivudine, zidovudine. Pts. with
abnormal. low neutrophil counts (less
than 0.75 x 109/l), or abnormal. low Hb
levels (less than 7.5g/dl or 4.65 mmol/l).
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Zidovudine 100 mg, 250 mg. CAPS.: 100 ×100 mg, 40 ×250 mg.
Adults and adolecs.> 30 kg: 250-
300 mg 2 x dly.
Child 8-13 kg: 100 mg 2 x dly. 14- 21 kg: 100 mg morn. + 200 mg evening. 22-30 kg: 200 mg 2 x dly. 28—30 kg: 250 mg 2 x dly. in comb. with other anti-retrov. agent.
In combin. with anti-retroviral tmt
for HIV infected adults and children. for
use in HIV-+tive pregn. women (over 14
wks of gestat.) for prevent. of maternal-foetal HIV transmiss. and for prim. prophyl.
of HIV infect. in newborn infants.
C/I: Hypersens., abnorm. low neutrophil
counts (< 0.75 x 109/L) or abnorm. low
HGB levels (less than 7.5 g/dL or 4.65
mmol/L). Oral formul.- also: newborn
infants with hyperbilirubin. requir. tmt
other than phototherapy, or with
increase. transaminase levels of over 5
times the upper limit of normal.